Headlands Research has announced the acquisition of AMCR Institute, which has been in operation for more than 20 years. The site’s team brings experience in metabolic, endocrine, and medical device research to the growing clinical research site network.
Led by principal investigator (PI) Timothy S. Bailey, MD, FACE, FACP, CPR, the San Diego–based clinical research site specializes in metabolic, endocrine, and other chronic conditions such as type 1 and type 2 diabetes and obesity. Bailey is a board-certified endocrinologist and is certified by the Association of Clinical Research Professionals (ACRP). He and his staff have worked with thousands of volunteers in Phase I-IV trials and have extensive experience with the evaluation of medical devices such as continuous glucose monitors (CGMs).
The acquisition of AMCR Institute, now known as Headlands Research AMCR Institute, is the most recent as the company expands its clinical research site network to support more clinical trials and provide access to investigational therapies to a diverse, representative population. Headlands Research recently launched one new clinical research site and acquired two additional established sites: Headlands Research Detroit serves multiple therapeutic areas, including Alzheimer’s disease and vaccines; Headlands Research Eastern Massachusetts specializes in neurodegenerative diseases such as Alzheimer’s disease, and Clinvest Research specializes in chronic diseases including migraine and arthritis.
Headlands Research Acquires AMCR Institute, Adding Medical Device Expertise to the Clinical Research Site Network. (2023, July 27). Business Wire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access